Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1471-1480

  Yallapu, Murali M ^a,d   Ebeling, Mara C ^a   Khan, Sheema ^a,d   Sundram, Vasudha ^a   Chauhan, Neeraj ^a,d   Gupta, Brij K ^a   Puumala, Susan E ^b   Jaggi, Meena ^a,c,d   Chauhan, Subhash C ^a,c,d  

^a Cancer Biology Research Center   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; COLLAGEN TYPE 1; CURCUMIN; CYCLINE; MAGNETIC NANOPARTICLE; MUCIN 1; PLASMA PROTEIN; PROTEIN BCL XL; PROTEIN MCL 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ERYTHROCYTES; HUMANS; MAGNETITE NANOPARTICLES; MALE; MICE; PANCREATIC NEOPLASMS; PROTEIN BINDING; TISSUE DISTRIBUTION; TUMOR BURDEN; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882267305     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1227     Document Type: Article

References (47)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61: 212-36.
2. Whatcott CJ, Posner RG, Von Hoff DD, Han H. Desmoplasia and chemoresistance in pancreatic cancer. In:Grippo PJ, Munshi HG, editors. Pancreatic cancer and tumor microenvironment. Transworld Research Network, Trivandrum, India; 2012.
3. Bartholin L. Pancreatic cancer and the tumor microenvironment: Mesenchyme's role in pancreatic carcinogenesis. In:Grippo PJ, Munshi HG, editors. Pancreatic cancer and tumor microenvironment. Transworld Research Network, Trivandrum, India; 2012.
4. Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 2006; 58:231-41.
5. Ng J, Zhang C, Gidea-Addeo D, SaifMW. Locally advanced pancreatic adenocarcinoma: Update and progress. JOP 2012;13:155-8.
6. U.S. Food and Drug Administration. Food additive status list. Revised as of April 1. [Accessed on July 17, 2012.] http://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=182.20.
7. Joe B, Vijaykumar M, Lokesh BR. Biological properties of curcumincellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 2004;44:97-111.
8. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: A short review. Life Sci 2006;78:2081-7.
9. Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. J Postgrad Med 2003;49:222-8.
10. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": From kitchen to clinic. Biochem Pharmacol 2008;75:787-809.
11. Stan SD, Singh SV, Brand RE. Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol 2010;7:347-56.
12. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: A future nanomedicine for cancer. Drug Discov Today 2012;17:71-80.
13. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila) 2011;4:1158-71.
14. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. J Nanobiotechnology 2007;5:3.
15. Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong SM, Pramanik D, et al. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther 2010; 9:2255-64.
16. Dandawate PR, Vyas A, Ahmad A, Banerjee S, Deshpande J, Swamy KV, et al. Inclusion complex of novel curcumin analogue CDF and betacyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Pharm Res 2012;29:1775-86.
17. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005;104:1322-31.
18. Zhang F, Koh GY, Jeansonne DP, Hollingsworth J, Russo PS, Vicente G, et al. A novel solubility-enhanced curcumin formulation showing stability and maintenance of anticancer activity. J Pharm Sci 2011;100: 2778-89.
19. Yallapu MM, Othman SF, Curtis ET, Gupta BK, Jaggi M, Chauhan SC. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials 2011;32:1890-905.
20. Yallapu MM, Foy SP, Jain TK, Labhasetwar V. PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharm Res 2010;27:2283-95.
21. Chauhan SC, Ebeling MC, Maher DM, Koch MD, Watanabe A, Aburatani H, et al. MUC13 mucin augments pancreatic tumorigenesis. Mol Cancer Ther 2012;11:24-33.
22. Sundram V, Chauhan SC, Ebeling M, Jaggi M. Curcumin attenuates beta-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS One 2012;7:e35368.
23. Chauhan SC, Vannatta K, Ebeling MC, Vinayek N, Watanabe A, Pandey KK, et al. Expression and functions of transmembrane mucinMUC13in ovarian cancer. Cancer Res 2009;69:765-74.
24. Sandell EB. Colorimetric determination of traces of metals. 3rd ed.New York: Interscience Publishers Inc.; 1959.
25. Yallapu MM, Ebeling MC, Chauhan N, Jaggi M, Chauhan SC. Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes. Int J Nanomedicine 2011;6:2779-90.
26. Jain TK, Richey J, Strand M, Leslie-Pelecky DL, Flask CA, Labhasetwar V. Magnetic nanoparticles with dual functional properties: Drug delivery and magnetic resonance imaging. Biomaterials 2008;29:4012-21.
27. Cheng J, Cheng L, Chen B, Xia G, Gao C, Song H, et al. Effect of magnetic nanoparticles of Fe(3)O(4) and wogonin on the reversal of multidrug resistance in K562/A02 cell line. Int J Nanomed 2012;7: 2843-52.
28. Yamauchi J, Kanai M, Matsumoto S, Nishimura T, Yazumi S, Kami K, et al. Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer. Pancreas 2008;36:327-8.
29. Jonckheere N, Skrypek N, Seuningen IV. Mucins and pancreatic cancer. Cancers 2010;2:1794-812.
30. Xie X, Tao Q, Zou Y, Zhang F, Guo M, Wang Y, et al. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: Characterizations and mechanisms. J Agric Food Chem 2011;59:9280-9.
31. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol 2012;69: 65-70.
32. Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, Nilsson H, et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A 2007;104:2050-5.
33. Leung MH, Kee TW. Effective stabilization of curcumin by association to plasma proteins: Human serum albumin and fibrinogen. Langmuir 2009;25:5773-7.
34. Batrakova EV, Li S, Brynskikh AM, Sharma AK, Li Y, Boska M, et al. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release 2010;143:290-301.
35. Das M, Sahoo SK. Folate decorated dual drug loaded nanoparticle: Role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One 2012;7:e32920.
36. Dilnawaz F, Singh A, Sahoo SK. Transferrin-conjugated curcuminloaded superparamagnetic iron oxide nanoparticles induce augmented cellular uptake and apoptosis in K562 cells. Acta Biomater 2012;8:704-19.
37. Smith JP, Kanekal S, PatawaranMB, Chen JY, Jones RE, Orenberg EK, et al. Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts. Cancer Chemother Pharmacol 1999;44:267-74.
38. Shahani K, Swaminathan SK, Freeman D, Blum A, Ma L, Panyam J. Injectable sustained release microparticles of curcumin: A new concept for cancer chemoprevention. Cancer Res 2010;70:4443-52.
39. Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, et al. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: A phase I/II study. Gastrointest Endosc 2012;75:332-8.
40. Jaggi M, Chauhan SC, Du C, Balaji KC. Bryostatin 1 modulates betacatenin subcellular localization and transcription activity through protein kinase D1 activation. Mol Cancer Ther 2008;7:2703-12.
41. Morris JP, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010;10:683-95.
42. Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011;30:1449-59.
43. Kufe DW. Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer 2009;9:874-85.
44. Zidar N, Gale N, Kambic V, Fischinger J. Proliferation of myofibroblasts in the stroma of epithelial hyperplastic lesions and squamous carcinoma of the larynx. Oncology 2002;62:381-5.
45. Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 2004;10:7427-37.
46. Polyak B, Friedman G. Magnetic targeting for site-specific drug delivery: Applications and clinical potential. Expert Opin Drug Deliv 2009; 6:53-70.
47. Dell'Orco D, Lundqvist M, Oslakovic C, Cedervall T, Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One 2010;5:e10949.